FDA Arthritis Advisory Committee
Will meet on Dec. 6 to discuss guidelines for analgestic drugs (see related T&G-1) and clinical requirements for topical OTC nonsteroidal anti-inflammatory drugs. The committee will also consider ICN's Oxsoralen (methoxalen) and J&J-Therakos' UVAR photophoresis devise for scleroderma. On Dec. 7, the committee will meet in closed session. The meeting begins at 8:30 a.m. at the Holiday Inn in Bethesda, Maryland.
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.